Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context

Abstract

Aim: To estimate real-world cardiovascular disease (CVD) burden and value-based price range of evolocumab for a US-context, high-risk, secondary-prevention population. Materials and methods: Burden of CVD was assessed using the UK-based Clinical Practice Research Datalink (CPRD) in order to capture complete CV burden including CV mortality. Patients on standard of care (SOC; high-intensity statins) in CPRD were selected based on eligibility criteria of FOURIER, a phase 3 CV outcomes trial of evolocumab, and categorized into four cohorts: high-risk prevalent atherosclerotic CVD (ASCVD) cohort (n ¼ 1448), acute coronary syndrome (ACS) (n ¼ 602), ischemic stroke (IS) (n ¼ 151), and heart failure (HF) (n ¼ 291) incident cohorts. The value-based price range for evolocumab was assessed using a previously published economic model. The model incorporated CPRD CV event rates and considered CV event reduction rate ratios per 1 mmol/L reduction in low-density lipoprotein-cholesterol (LDL-C) from a meta-analysis of statin trials by the Cholesterol Treatment Trialists Collaboration (CTTC), i.e. CTTC relationship. Results: Multiple-event rates of composite CV events (ACS, IS, or coronary revascularization) per 100 patient-years were 12.3 for the high-risk prevalent ASCVD cohort, and 25.7, 13.3, and 23.3, respectively, for incident ACS, IS, and HF cohorts. Approximately one-half (42%) of the high-risk ASCVD patients with a new CV event during follow-up had a subsequent CV event. Combining these real-world event rates and the CTTC relationship in the economic model, the value-based price range (credible interval) under a willingness-to-pay threshold of $150,000/quality-adjusted life-year gained for evolocumab was $11,990 ($9,341-$14,833) to $16,856 ($12,903-$20,678) in ASCVD patients with baseline LDL-C levels !70 mg/dL and !100 mg/dL, respectively. Conclusion: Real-world CVD burden is substantial. Using the observed CVD burden in CPRD and the CTTC relationship, the cost-effectiveness analysis showed that, accounting for uncertainties, the expected value-based price for evolocumab is higher than its current annual cost, as long as the payer discount off list price is greater than 20%. ARTICLE HISTORY

Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years*

“…A previously published Markov cohort state transition model [19–21] was adapted, considering a Bulgarian payer perspective and a life-long treatment duration. The model employs annual cycles (with a half-cycle correction [22]) and was built using Microsoft Excel 2010 (Microsoft Corp., Redmond, WA).…”

Real-world cardiovascular disease burden in patients with atherosclerotic cardiovascular disease: a comprehensive systematic literature review

“…For the long-term period, patients with score 0 had 111, score 1 had 126, and score 2þ had 196 multiple MACEs per 1000 personyears. Toth et al 31 assessed UK data from CPRD, HES and the Office for National Statistics from 2004 to 2011. High-intensity statin treated patients with LDL-C 70 mg/dL or other dyslipidemias were categorized into high-risk ASCVD, incident ACS, incident ischemic stroke, and incident heart failure cohorts.…”

PCSK9 inhibitor valuation: A science‐based review of the two recent models

“…The ICER analysis (Kazi et al 42 ) relied on the Coronary Heart Disease Policy Model published 30 years ago. 43 This is in contradistinction to the model employed by Fonarow et al, 44 which is based on Gandra et al, 45 Toth et al, 46 reveal, however, that they have already reached that benchmark. The exact price paid by pharmacy benefit managers is not publicly disclosed.…”